The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancerTheodora A. Constantin(Hammersmith Hospital), Charlotte L. Bevan(Imperial College London)British Journal of CancerApril 19, 202310.1038/s41416-023-02252-8Cited by 24SaveCiteExport RISWatch citationsRelated PapersAndrogen receptor-modulatory microRNAs provide insight into therapy resistance and therapeutic targets in advanced prostate cancer|Oncogene|2019|70Manipulating prohibitin levels provides evidence for an in vivo role in androgen regulation of prostate tumours|Endocrine Related Cancer|2009|56